Why It Matters
SkinCure Oncology LLC terminated its in-house lobbying registration on June 30, ending its efforts to advocate for Medicare coverage of Image-Guided Superficial Radiation Therapy (IGSRT), a treatment for non-melanoma skin cancer.
By The Numbers
The company spent $370,000 on lobbying in 2025 and $130,000 in the termination filing. SkinCure Oncology retained four lobbying firms, Armory Hill Advocates, Wells Health Group LLC, HB Strategies, and AxAdvocacy LLC, alongside in-house lobbying conducted by the company itself.
Broader Context
SkinCure Oncology's lobbying efforts focused on education and information provision regarding IGSRT while working on a coverage policy with the Centers for Medicare & Medicaid Services (CMS). The company's lobbying disclosures contained no specific legislation references. In March 2026, SkinCure Oncology filed a lawsuit against the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) challenging recent changes to Medicare reimbursements for Image-Guided Superficial Radiation Treatment (IGSRT). SkinCure Oncology and other plaintiffs sought a federal court injunction to stop efforts to strip Medicare coverage for IGSRT. A federal court denied the requested injunction in the case challenging Medicare reimbursement changes for IGSRT. Proposed Local Coverage Determinations (LCDs) would strip Medicare coverage for IGSRT in Medicare Administrative Contractor (MAC) jurisdictions if finalized.
The Bottom Line
A federal court denied the requested injunction in the case challenging Medicare reimbursement changes for image-guided superficial radiation therapy.
Spot something wrong? Report an issue with this article